1. European Urology Oncology
Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study 
Thomas Loubersac, Molière Nguile-Makao, Frédéric Pouliot, Vincent Fradet, Paul Toren 
European Urology Oncology 
DOI: /j.euo
Copyright © 2019 European Association of Urology Terms and Conditions

2. Fig. 1 CONSORT diagram of patients included in the analysis.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions

3. Fig. 2
Neutrophil:lymphocyte ratio at screening, at the beginning of cycle 2, and at the end of the study by treatment arm. No significant differences between treatment arms were observed, but significant differences (***p<0.001) were observed between indicated time points. AA=abiraterone acetate.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions

4. Fig. 3
Neutrophil:lymphocyte ratio (NLR) as a predictive biomarker of response to abiraterone therapy. Kaplan-Meier survival curves showing differential responses to abiraterone acetate plus prednisone but not to placebo plus prednisone when stratified by baseline neutrophil:lymphocyte ratio. (A) Overall survival. (B) Time to radiographic progression. (C) Time to PSA progression. AA=abiraterone acetate; PSA=prostate-specific antigen.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions

5. Fig. 4
Effect of changes in neutrophil:lymphocyte ratio (NLR) on subsequent benefit of abiraterone acetate. Survival was calculated from the first absolute change of NLR from baseline under prednisone treatment on the 1st day of cycle 2 in the COU302 trial. Only patients with indicated changes are included in survival analysis. AA=abiraterone acetate; PSA=prostate-specific antigen.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions